EXSCIENTIA
Professor Andrew Hopkins FRS FMedSci, founder and Chief Executive of Exscientia plc (Nasdaq: EXAI), has been appointed Commander of the Order of the British Empire (CBE) for services to Science and Innovation by His Majesty King Charles III. The distinguished honour comes as part of HM The King’s 2024 New Year Honours List, recognising the achievements and service of extraordinary people across the UK who have been recommended by the Prime Minister based on an independent assessment process.
The appointment reflects Andrew’s life-long passion for harnessing the power of innovative technologies to discover and develop high-quality medicines to benefit patients. This recognition follows multiple previous awards and prestigious honours recently received by both Andrew and Exscientia, the AI-driven precision medicine company he leads.
After publishing pioneering scientific papers on how machine learning and generative algorithms could be used to design novel drug leads, Andrew founded Exscientia in 2012 to create and develop the best possible drugs in the fastest and most effective manner. As the company’s CEO, Andrew led the group who discovered the first AI-designed drugs to enter human clinical trials. Today, he heads a global team of around 450 scientists and technology experts based in Oxford, UK, and globally. Prior to Exscientia, Andrew held the Chairs of Medicinal Informatics and Translational Biology at the University of Dundee and spent a decade at Pfizer Inc. leading various informatics groups. He received his doctorate in biophysics from the University of Oxford and his LLD from the University of Dundee where he also holds an Honorary Chair.
For its end-to-end AI-driven precision medicine platform, Exscientia won the Prix Galien USA for Best Digital Health Solution in late 2022, as well as the Prix Galien UK in the same category in May 2023. Also in May this year, Andrew was elected for life to two of the UK’s national academies in recognition of “exceptional contributions to science”, as Fellow of the Royal Society, the world’s oldest independent academic scientific body, and as Fellow of the Academy of Medical Sciences. In September, Andrew was featured on the inaugural TIME 100 AI list of most influential people in AI, while most recently, in November 2023, Exscientia was named to the inaugural Fortune 50 AI Innovators list.
“I’m truly humbled by this extraordinary recognition of the work of my outstanding team that I am privileged to lead,” said Andrew. “Our goal at Exscientia of utilising advanced technology to accelerate the design of new drugs, an idea that originated during my doctorate, has gained substantial momentum in changing the way future therapies may be created, evaluated and brought to patients in need of fast, effective and affordable treatment. Based on our progress so far, we believe all drugs will be designed and developed with AI and that this approach holds the key to transforming the trajectory of human health forever.”
About Exscientia
Exscientia is an AI-driven precision medicine company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Our internal pipeline is focused on leveraging our precision medicine platform in oncology, while our partnered pipeline broadens our approach to other therapeutic areas. By pioneering a new approach to medicine creation, we believe the best ideas of science can rapidly become the best medicines for patients. Visit us at https://www.exscientia.ai or follow us on Twitter @exscientiaAI.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240102661842/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fujirebio Acquires Plasma Services Group and Strengthens Its Position as Provider of Critical and High Quality Biological Raw Materials to the IVD and Life Science Industries23.6.2025 13:00:00 CEST | Press release
H.U. Group Holdings Inc., and its wholly owned subsidiary, Fujirebio Holdings, Inc. (hereinafter “Fujirebio”) today announced that Fujirebio Diagnostics, Inc., a subsidiary of Fujirebio, has acquired all shares of Plasma Services Group, Inc. (hereinafter “Plasma Services Group”). The transaction value has not been disclosed. Founded in 2004, Plasma Services Group has specialized in the collection, screening and supply of high quality and rare biological materials required for R&D and manufacturing in the in vitro diagnostics (IVD) and life science industries. The company is particularly well positioned in the field of rare diseases. From its state-of-the-art FDA registered, ISO certified facility in Moorestown, NJ, USA, Plasma Services Group provides sera and other samples for materials of control reagents and calibrators for a wide range of diseases and offers sample collection services globally. For more information about Plasma Services Group please visit www.plasmaservicesgroup.com
Compass Pathways Successfully Achieves Primary Endpoint in First Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression23.6.2025 12:30:00 CEST | Press release
A single administration of COMP360 demonstrated a highly statistically significant and clinically meaningful reduction in symptom severity as measured by MADRS1 with a mean difference of -3.6 comparing 25 mg to placebo (p<0.001)2Independent Data Safety Monitoring Board (DSMB) reviewed safety data for COMP360 and found no unexpected safety findings and no clinically meaningful imbalance in suicidal ideation between treatment and placebo armsOngoing pivotal Phase 3 COMP005 trial is the first study of an investigational, synthetic psilocybin, and the first classic psychedelic3, to report Phase 3 efficacy dataSecond ongoing pivotal Phase 3 COMP006 trial continues to enroll well, with 26-week data expected in the second half of 2026 Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the successful achievement of the primary endpoint in the ongoing Phase 3 COMP005 trial, the first of two Phase 3
IFF Opens New State-of-the-art Office in Hyderabad, India23.6.2025 12:00:00 CEST | Press release
Newly constructed site reflects the Company’s commitment to scaling its global business services operations. IFF (NYSE: IFF)--a global leader in flavors, fragrances, food ingredients, health and biosciences—has officially relocated its Global Business Services (GBS) center in Hyderabad to a newly constructed, state-of-the-art facility. This move marks a significant step in IFF’s strategy to drive operational excellence and innovation through agile corporate functions. The new 75,000 sq. ft. office located in Hyderabad’s prime financial district, is designed to accommodate up to 600 employees. It features cutting-edge infrastructure, collaborative workspaces and advanced technologies that support IFF’s global operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250623457977/en/ “This move enables us to serve our customers with greater speed, efficiency and purpose, while advancing strategic growth and sustainability,” s
Brighter Signals Emerges from Stealth23.6.2025 09:15:00 CEST | Press release
New High-Depth Tactile Sensor Platform Redefines Touch Sensing Across Robotics, Automotive, and Healthcare Brighter Signals B.V. (https://www.brightersignals.com), a sensing technology startup founded by serial entrepreneurs Andrew Klein, Christine Fraser and Edward Shim, today announced its launch and the acquisition of a breakthrough portfolio of patents for high-depth multi-modal tactile sensors made wholly of fabrics. Backed by early-stage VC firm Antler, Brighter Signals has developed a sensor platform over ten years that offers unprecedented high-depth tactile sensitivity, flexibility, and environmental sustainability. Unlike binary touch sensors, Brighter Signals’ technology captures nuanced pressure gradients in real-time and can be seamlessly integrated into fabrics, surfaces, and structures. The sensors are lightweight, durable, and fully recyclable. The company is initially focused on three industries: Robotics: enabling high-fidelity tactile sensing in grippers and humanoid
OLX Group Reports Strong FY 2025 Results With 18% Revenue Growth and 61% Profit Uplift Year-on-Year23.6.2025 09:00:00 CEST | Press release
OLX Group (“OLX”), a global online classifieds leader and subsidiary of Prosus N.V., has reported strong financial results in the fiscal year 20251. The company generated revenues of US$7772 million, an 18% year-on-year increase. Adjusted EBIT3 (aEBIT) amounted to US$2702 million, representing an increase of 61% (in local currency) over the prior year, while aEBIT margin was 35%, a significant expansion from 25% in FY24. The strong performance was primarily driven by its core categories Motors, Real Estate, and Jobs, in its key high-growth markets. In addition, the company continues to leverage its strong investments in product, with emphasis on enhancing the customer and user experience through state-of-the-art AI solutions. Main categories essential for driving growth and profitability Across its platforms, OLX witnessed strong user and customer engagement. OLX platforms, operating nine brands in nine markets worldwide, hosted nearly 64 million active listings daily, with 29 million
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom